The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- Ex-Health Minister Otsuji to Retire from Politics Next Summer
July 10, 2024
- PMDA to Push Simultaneous Development of Pediatric Drugs via New Consultation Center
July 9, 2024
- LDP Group Renews Call for Gender-Neutral HPV Vaccination
July 9, 2024
- MHLW Proposes New Scheme for Development Requests to Fight Drug Loss
July 8, 2024
- Breyanzi’s Label Expansion Up for MHLW Panel Review on July 19
July 8, 2024
- Panelists Wary of Proposed Switch of Generic GMP Inspection Authority to PMDA
July 8, 2024
- Minister Nudges Generic Product Consolidation, Pitches “5 Makers per API”
July 5, 2024
- LDP Veteran Seiichi Eto to Bow Out from Politics Next Summer
July 5, 2024
- Payer Chides AnGes’s Course Change on Collategene, Urges Re-Think of System’s Set-Up
July 4, 2024
- Over 60% of Generic Firms Carry Jointly Developed Products, 98% of Espha Drugs Fall into This Category
July 3, 2024
- LDP Group Calls for MCI Screening for Early Detection of Alzheimer’s
July 3, 2024
- New ICH Topic on RWD to Be Proposed towards Its Use in Regulatory Review
July 2, 2024
- Sato Named MHLW’s Top Pharmacy Officer; Kiyohara to Steer Drug Pricing Reform
July 2, 2024
- MHLW Shuffles Senior Bureaucrats, Ihara Tapped as Vice Health Minister
July 2, 2024
- PMDA Kicks Off Consultations for Pediatric and Rare Disease Drugs
July 2, 2024
- PMDA Opens 1st Overseas Office in Bangkok
July 2, 2024
- Minister Wants Consensus on Future Generic Industry at Upcoming Confab
July 1, 2024
- MHLW to Revise Process to Share Info on Nitrosamine Impurities after Guidance Issued
June 28, 2024
- MHLW Project Team Proposes New Subsidies for Early R&D of Intractable Disease Drugs
June 28, 2024
- MHLW Sets Up Global Strategy HQ to Bolster Innovation Ecosystem
June 28, 2024
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…